Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®: A Retrospective Study (PROTRACT)
Latest Information Update: 16 Jan 2020
At a glance
- Drugs Dimethyl fumarate (Primary) ; Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms PROTRACT
- 28 Feb 2018 Status changed from active, no longer recruiting to completed.
- 14 Jun 2017 Planned End Date changed from 1 May 2017 to 1 Jul 2017.
- 14 Jun 2017 Status changed from recruiting to active, no longer recruiting.